http://localhost:80/xmlui/handle/123456789/12743 2026-04-23T12:42:59Z http://localhost:80/xmlui/handle/123456789/15067 Title: Antiviral, embryo toxic and cytotoxic activities of Astragalus membranaceus root extracts Authors: Raza, Syeda Maryam; Anjum, Aftab Ahmad; Ali, Muhammad Asad; Akbar, Hamid; Khan, Humaira Majeed Abstract: Antiviral activity of Astragalus membranaceus aqueous and methanol root extracts was determined against Avian influenza H9 virus. Toxicity profile of extracts was evaluated using chicken embryos and BHK-21 cell line. Different concentrations (400, 200, 100, 50, 25. 12.5, 6.25 and 3.12µg/mL) of both aqueous and methanol extracts were mixed with standard virus inoculum (4HAunits) and incubated for 30minutes at 37oC prior to inject the chicken embryos. Chorioallantoic fluid harvested 72 hours post inoculation and evaluated for virus growth using hemagglutination assay. Same concentrations of both extracts without virus were injected in chicken embryos to evaluate embryo toxic activity as well. The cytotoxic activity of aqueous and methanol extracts was determined by MTT colorimetric assay using BHK-21 cells. Three concentrations (400, 200 and 100µg/mL) of aqueous and five concentrations (400, 200, 100, 50 and 25µg/mL) of methanol extract showed antiviral activity. None of the tested concentrations of aqueous and methanol A. membranaceus root extracts caused chicken embryo mortality. Cell survival percentage of aqueous extract was higher than 50 at all of the tested concentrations except 400µg/mL. Two concentrations (400 and 200µg/mL) of methanol extract showed cytotoxicity. It was concluded that aqueous and methanol roots extracts of A. membranaceus have antiviral activity and concentrations which were safe may be used for treatment of Avian influenza H9 virus infections. 2019-01-20T00:00:00Z http://localhost:80/xmlui/handle/123456789/15064 Title: Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens Authors: Bano, Nusrat; Ikram, Rahila Abstract: This retrospective study reports impact of diabetes on incidence rate of dose limiting symptoms of neurological toxicity and chemotherapy induced peripheral neuropathy (CIPN). Post-surgical colorectal cancer (CRC) patients with metastatic disease, treated with four different schedules of FOLFOX were included in this study. Neurological adverse effects were assessed by CTC v2.0. The incidence rate of adverse neurological symptoms in CRC patients, clinically diagnosed with diabetes (n=6) were compared with non-diabetic CRC patients (n=32). The results show that the difference in the incidence rate of paresthesia is significant (p=0.043) between diabetic and non-diabetic patients. The difference in the incidence rates of hypoesthesia (p=0.445), peripheral neuropathy (p=0.889), dizziness (p=0.445), insomnia (p=0.690), taste disturbances (p=0.258), and headache (p=0.498) in diabetic and non-diabetic CRC patients was not significant. The findings indicate that risk of frequent, distal and transient paresthesia within the first few minutes of Oxaliplatin infusion is higher in diabetic CRC patients. 2019-01-18T00:00:00Z http://localhost:80/xmlui/handle/123456789/15062 Title: Formulation development and in-vitro evaluation of fast dispersible, taste masked Aceclofenac compacted pellets Authors: Yasmin, Riffat; Shoaib, Muhammad Harris; Qazi, Faaiza; Nasiri, Muhammad Iqbal; Ali, Tariq; Zafar, Farya Abstract: The objective of this study was to develop Aceclofenac fast dispersible compacted pellets with improved taste and fast drug release. Pellets were prepared by extrusion-spheronization technique followed by direct compression to make compacted pellets. Formulations were comprised of sucrose, mannitol, ac-di-sol, aspartame, pine apple flavor and magnesium stearate. A mixture of distilled water and isopropyl alcohol (1:1) was used for wet massing. The effect of acdi-sol on the drug release pattern was examined and dissolution profile comparison was established. All formulations followed First order and Weibull models and f2 values indicated dissimilarity with the marketed immediate release product. Taste of compacted pellets was evaluated by a panel of 12 human volunteers. Formulation P5 was found to be an optimized formulation due to satisfactory quality attributes. 2019-01-17T00:00:00Z http://localhost:80/xmlui/handle/123456789/15059 Title: Antimicrobial, antiquorum sensing and antiproliferative activities of sesquiterpenes from Costus speciosus rhizomes Authors: Ibrahim, Sabrin Ragab Mohamed; El-Shaer, Nagwa Salah Al-Din Ahmed; Asfour, Hani Zakaria; Elshali, Khalid Zaki; Shaaban, Mona Ibrahim Awad; Al-Attas, Ahmed Alawi Mohsen; Mohamed, Gamal Abd Allah Abstract: The quorum sensing inhibitory (QSI) and antimicrobial potentials of the total methanol extract (TME) and different extractives as well as the sesquiterpenes: dehydrodihydrocostus lactone (1), dehydrocostus lactone (2), arbusculin A (3), santamarine (4), reynosin (5), and specioic acid (6) isolated from Costus speciosus rhizomes were evaluated. The CHCl3:EtOAc (1:1), EtOAc, and TME fractions exhibited potent antibacterial activity toward B. cereus with inhibition zone diameter 13 mm. While the CHCl3 fraction showed strong activity towards S. aureus and B. cereus with inhibition zone diameter 11 and 19 mm, respectively. Moreover, the TME and CHCl3 fractions have strong activity towards C. albicans with inhibition zone diameter 15 and 12 mm, respectively. Compound 5 showed prominent activity towards B. cereus (MIC 385 µg/mL). However, 6 exhibited significant activity with MIC values of 150, 400, and 550 µg/mL towards S. aureus, E. coli, and B. cereus, respectively. Moreover, it showed potent antifungal effect towards C. albicans (MIC 320 µg/mL). Most of the tested fractions had QSI activity against C. violaceum. Only compound 6 exhibited moderate QSI effect with disappearance of violet pigment. In addition, compounds 1-6 were evaluated for their in vitro antiproliferative activity towards KB, BT-549, SK-MEL, and SKOV-3 cancer cell lines. 2019-01-16T00:00:00Z